The yin yang of sunitinib: One drug, two doses, and multiple outcomes

Our recent work showed that sunitinib exerts dual effect on cancer cells in different dose ranges. In clinically relevant doses, cancer cells tolerate sunitinb cytotoxicity by upregulating pro-survival MCL-1 and activating mTORC1 signaling. Inhibition of MCL-1 or mTORC1 sensitized cancer cells to su...

Descripción completa

Detalles Bibliográficos
Autor principal: Elgendy, Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383356/
https://www.ncbi.nlm.nih.gov/pubmed/28401187
http://dx.doi.org/10.1080/23723556.2017.1285385
_version_ 1782520272168943616
author Elgendy, Mohamed
author_facet Elgendy, Mohamed
author_sort Elgendy, Mohamed
collection PubMed
description Our recent work showed that sunitinib exerts dual effect on cancer cells in different dose ranges. In clinically relevant doses, cancer cells tolerate sunitinb cytotoxicity by upregulating pro-survival MCL-1 and activating mTORC1 signaling. Inhibition of MCL-1 or mTORC1 sensitized cancer cells to sunitinib. Analysis of tissues from patients correlated MCL-1/mTORC1 induction with resistance to sunitinib.
format Online
Article
Text
id pubmed-5383356
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-53833562018-02-23 The yin yang of sunitinib: One drug, two doses, and multiple outcomes Elgendy, Mohamed Mol Cell Oncol Commentary Our recent work showed that sunitinib exerts dual effect on cancer cells in different dose ranges. In clinically relevant doses, cancer cells tolerate sunitinb cytotoxicity by upregulating pro-survival MCL-1 and activating mTORC1 signaling. Inhibition of MCL-1 or mTORC1 sensitized cancer cells to sunitinib. Analysis of tissues from patients correlated MCL-1/mTORC1 induction with resistance to sunitinib. Taylor & Francis 2017-02-23 /pmc/articles/PMC5383356/ /pubmed/28401187 http://dx.doi.org/10.1080/23723556.2017.1285385 Text en © 2017 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Commentary
Elgendy, Mohamed
The yin yang of sunitinib: One drug, two doses, and multiple outcomes
title The yin yang of sunitinib: One drug, two doses, and multiple outcomes
title_full The yin yang of sunitinib: One drug, two doses, and multiple outcomes
title_fullStr The yin yang of sunitinib: One drug, two doses, and multiple outcomes
title_full_unstemmed The yin yang of sunitinib: One drug, two doses, and multiple outcomes
title_short The yin yang of sunitinib: One drug, two doses, and multiple outcomes
title_sort yin yang of sunitinib: one drug, two doses, and multiple outcomes
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383356/
https://www.ncbi.nlm.nih.gov/pubmed/28401187
http://dx.doi.org/10.1080/23723556.2017.1285385
work_keys_str_mv AT elgendymohamed theyinyangofsunitinibonedrugtwodosesandmultipleoutcomes
AT elgendymohamed yinyangofsunitinibonedrugtwodosesandmultipleoutcomes

Ejemplares similares